Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Table 3 Tumor response rate and long-term outcome

Measured outcomes	Studies, n	Heterogeneity test, I2 (%)	Heterogeneity test, P value	Model	RR/HR	95%CI	P value
Complete response	6	0	0.95	Random	1,81	1.11-2.96	0.02
Partial response	6	0	0.78	Random	1.38	1.12-1.70	0.002
Stable disease	6	50	0.08	Random	0.89	0.60-1.33	0.58
Progressive disease	6	0	0.67	Random	0.54	0.39-0.74	0.0002
Objective response rate	6	0	0.80	Random	1.47	1.24-1.74	< 0.0001
Disease control rate	6	82	< 0.0001	Random	1.22	1.00-1.49	0.05
Overall survival	4	39.8	0.173	Random	0.28	0.19-0.42	< 0.05
Disease free survival	4	0	0.482	Random	0.54	0.42-0.69	< 0.05

RR/HR: Relative risk /hazard ratio; CI: Confidence interval.